- Title: Subtitle
- 73MO Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12C–mutated metastatic colorectal cancer (mCRC): Regional analysis of safety and efficacy from CodeBreaK 101
- Creators
- T. Masuishi - Aichi Cancer CenterK. Yamaguchi - The Cancer Institute HospitalJ.C. Ruffinelli Rodriguez - Institut Català d'OncologiaE. Corral de la Fuente - Hospital Universitario Ramón y CajalY. Kuboki - National Cancer Center Hospital EastC. Cremolini - University of PisaI. Victoria Ruiz - Hospital Clínic de BarcelonaM.E. Elez Fernandez - Hebron UniversityJ.H. Strickler - Duke Cancer InstituteM. Furqan - Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USAB. Bashir - Thomas Jefferson UniversityC. Nduka - Global Safety, Amgen - UK, Uxbridge, UKJ. Hippenmeyer - Amgen (Switzerland)E. Chan - Amgen (United States)C. Xia - Amgen (United States)S. Siena - University of Milan
- Resource Type
- Abstract
- Publication Details
- Annals of oncology, Vol.35(Supplement 4), pp.S1432-S1432
- DOI
- 10.1016/j.annonc.2024.10.095
- ISSN
- 0923-7534
- eISSN
- 1569-8041
- Publisher
- Elsevier Ltd; AMSTERDAM
- Grant note
- Amgen Inc.
Amgen Inc.
- Language
- English
- Date published
- 12/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984757687402771
Abstract
73MO Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12C–mutated metastatic colorectal cancer (mCRC): Regional analysis of safety and efficacy from CodeBreaK 101
Annals of oncology, Vol.35(Supplement 4), pp.S1432-S1432
12/2024
DOI: 10.1016/j.annonc.2024.10.095
Details
Metrics
18 Record Views